Achieving Global Health Equity Through More Diverse and Inclusive Trials

Health equity requires every moving piece of the healthcare ecosystem, including pharma companies. But ensuring a more equitable and accessible healthcare system starts for pharma at the beginning. It starts with the HCPs you engage for pre-drug launch and marketing; it starts with the site investigators you recruit; it starts with the location and availability of the study. It comes down to a basic ABC(D) equation. D=diversity.

In this informative event we’ll explore:

• Historically, what has been lacking in clinical trials when it comes to diversity and inclusion
• Why it took federal guidelines to begin to turn the conversation toward pharma and health equity
• How big data can fuel trial diversity and why the data matters as well as a case study
• What the ABC(and D’s) are of clinical trial diversity, equity, access, and inclusion
• Why geography and patient representation matter